World First Male Contraceptive Enters Clinical Trials
- Paternal Microbiome Perturbations Impact Offspring Fitness
- New Report Casts Doubt on Maradona’s Cause of Death and Rocks Manslaughter Case
- Chinese academician unable to provide the exact source of liver transplants
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
World First Male Contraceptive Enters Clinical Trials
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
World First Male Contraceptive Enters Clinical Trials
The world’s first male contraceptive is on the horizon, as it has officially entered clinical trials.
According to the University of Minnesota, a male contraceptive named YCT-529, developed by YourChoice Therapeutics, has commenced its Phase 1 clinical trials in the United Kingdom this week.
The drug’s tolerance, safety, pharmacokinetics, and efficacy will be evaluated in a cohort of 16 male participants. This marks the first non-hormonal male contraceptive to undergo clinical trials globally.
Historically, male contraceptives in clinical trials have been hormonal, exhibiting limited effectiveness and severe side effects.
Over the past few decades, from birth control pills to patches and intrauterine devices, women have borne the majority of the contraceptive burden.
Male contraceptive options have primarily included condom usage and vasectomy, but the irreversible nature of vasectomy has led to lower acceptance among men.
YCT-529, a collaboration between Professor Gunda Georg of the University of Minnesota and YourChoice Therapeutics, is a retinoic acid receptor inhibitor that prevents sperm formation by blocking the acquisition of vitamin A.
World First Male Contraceptive Enters Clinical Trials
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
